Recruiting Rheumatoid Arthritis Studies in Richmond
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipient...
Study to Assess SLN124 in Patients With Polycythemia Vera
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to ...
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is s...
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
The study regimen will be administered on an outpatient basis and all medications are administered intravenously (IV). Subjects will receive treatment on Day 1 and Day 15 of each 28-day cycle consisti...
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients w...
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney t...
About Rheumatoid Arthritis Clinical Trials in Richmond
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 6 rheumatoid arthritis clinical trials recruiting participants in Richmond, VIRGINIA. These studies are seeking a combined 561 participants. Research is being sponsored by University of California, San Francisco, Silence Therapeutics plc, Major Extremity Trauma Research Consortium and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in Richmond — FAQ
Are there rheumatoid arthritis clinical trials in Richmond?
Yes, there are 6 rheumatoid arthritis clinical trials currently recruiting in Richmond, VIRGINIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Richmond?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Richmond research site will contact you about next steps.
Are clinical trials in Richmond free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Richmond studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 6 active trials in Richmond are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated March 2, 2026 from ClinicalTrials.gov